Third Quarter Financial Report - 2018 | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
17779
post-template-default,single,single-post,postid-17779,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Third Quarter Financial Report – 2018

Third Quarter Financial Report – 2018

Moss, 16.11.2018

Gentian Diagnostics AS announces its results for the third quarter of 2018. The highlights include:

  • Total revenues of MNOK 18.4 including a one-off license revenue of MNOK 6.2
  • Record sales revenues of MNOK 10.4 for the quarter
  • 55% growth in underlying sales revenue compared to 3Q17, 43 % year to date
  • Clinical study program for GCAL is progressing according to plan

Please find the report GD-3Q2018-Interim-report.

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525